Comparing CannTrust (OTCMKTS:CNTTF) and InMed Pharmaceuticals (NASDAQ:INM)

CannTrust (OTCMKTS:CNTTFGet Free Report) and InMed Pharmaceuticals (NASDAQ:INMGet Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Volatility and Risk

CannTrust has a beta of 4.52, meaning that its stock price is 352% more volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500.

Valuation and Earnings

This table compares CannTrust and InMed Pharmaceuticals’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CannTrust $15.96 million 63.54 $7.39 million $0.07 137.18
InMed Pharmaceuticals $5.63 million 0.38 -$7.95 million N/A N/A

CannTrust has higher revenue and earnings than InMed Pharmaceuticals.

Profitability

This table compares CannTrust and InMed Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CannTrust N/A N/A N/A
InMed Pharmaceuticals -108.02% -53.42% -45.36%

Analyst Recommendations

This is a breakdown of recent ratings for CannTrust and InMed Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CannTrust 0 0 0 0 N/A
InMed Pharmaceuticals 0 0 0 0 N/A

Insider & Institutional Ownership

0.1% of CannTrust shares are held by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are held by institutional investors. 1.4% of InMed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

CannTrust beats InMed Pharmaceuticals on 7 of the 9 factors compared between the two stocks.

About CannTrust

(Get Free Report)

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

About InMed Pharmaceuticals

(Get Free Report)

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Receive News & Ratings for CannTrust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CannTrust and related companies with MarketBeat.com's FREE daily email newsletter.